Connection

Raymond DuBois to Isoenzymes

Back to Details
This is a "connection" page, showing publications Raymond DuBois has written about Isoenzymes.
Raymond DuBois
Connection Strength
3.166
Isoenzymes
  1. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005 Jan 10; 23(2):254-66.
    View in: PubMed
    Score: 0.222
  2. Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Gastroenterology. 2004 Nov; 127(5):1391-400.
    View in: PubMed
    Score: 0.219
  3. Cyclooxygenase as a target in lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4266s-4269s.
    View in: PubMed
    Score: 0.213
  4. Cyclooxygenase-2 in lung carcinogenesis and chemoprevention: Roger S. Mitchell lecture. Chest. 2004 May; 125(5 Suppl):134S-40S.
    View in: PubMed
    Score: 0.212
  5. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 2004 May-Jun; 10(3):145-52.
    View in: PubMed
    Score: 0.212
  6. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):415-6.
    View in: PubMed
    Score: 0.207
  7. Cyclooxygenase 2 (COX-2) as a target for therapy and noninvasive imaging. Mol Imaging Biol. 2003 Sep-Oct; 5(5):286-303.
    View in: PubMed
    Score: 0.202
  8. The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opin Emerg Drugs. 2003 May; 8(1):1-7.
    View in: PubMed
    Score: 0.197
  9. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003 Mar 01; 63(5):906-11.
    View in: PubMed
    Score: 0.195
  10. Cyclooxygenase-2 and colorectal cancer. Prog Exp Tumor Res. 2003; 37:124-37.
    View in: PubMed
    Score: 0.193
  11. New agents for cancer prevention. J Natl Cancer Inst. 2002 Dec 04; 94(23):1732-3.
    View in: PubMed
    Score: 0.192
  12. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. J Natl Cancer Inst. 2002 Mar 20; 94(6):406-7.
    View in: PubMed
    Score: 0.183
  13. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002; 42:55-80.
    View in: PubMed
    Score: 0.180
  14. Cyclooxygenase-2: a therapeutic target. Annu Rev Med. 2002; 53:35-57.
    View in: PubMed
    Score: 0.180
  15. COX-2 inhibition and colorectal cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 7):12-21.
    View in: PubMed
    Score: 0.053
  16. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):64-73.
    View in: PubMed
    Score: 0.052
  17. Will an aspirin a day keep the endoscope away? Gastroenterology. 2003 Aug; 125(2):612-4.
    View in: PubMed
    Score: 0.050
  18. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003 Sep 12; 278(37):35451-7.
    View in: PubMed
    Score: 0.050
  19. Evaluation of the whole prostaglandin biosynthetic pathway in lung cancer. Clin Cancer Res. 2003 May; 9(5):1577-8.
    View in: PubMed
    Score: 0.049
  20. New avenues for the prevention of colorectal cancer: targeting cyclo-oxygenase-2 activity. Best Pract Res Clin Gastroenterol. 2002 Dec; 16(6):945-56.
    View in: PubMed
    Score: 0.048
  21. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 2002 Jun 01; 62(11):3282-8.
    View in: PubMed
    Score: 0.046
  22. Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions. Surgery. 2003 May; 133(5):568-79.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.